A Supreme Court ruling gives drug companies more leeway to conduct research using patented substances from competitors.
Justices today unanimously reversed a lower court ruling in favor of a patent-holder (Integra LifeSciences Holdings Corporation).
It means big drug companies have more flexibility to start experimenting with potential therapies as long as they won't be marketed until a competitor's patent expires.
The patent-holder had accused a German company of infringing on a patent on certain molecules. Researchers hope the patented biological molecules can inhibit tumors.